Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access
The case is ‘existential for the generics market,’ said one legal expert
In a closely watched case, the U.S. solicitor general has urged the Supreme Court to review a controversy over so-called skinny labels for medicines, arguing that an appeals court finding threatens the availability of lower-cost generic drugs.